The research infrastructures ARIEL, ISAC, and MYRRHA collaborate in the production of rare radioisotopes
As part of the official state visit in Canada, TRIUMF and SCK•CEN – two of the leading scientific research institutes in the world – formalize their international collaboration to share their expertise in developing their respective research infrastructures, ARIEL and ISAC in Canada and MYRRHA in Belgium. These research infrastructures aim at developing the production of rare radio-isotopes and our knowledge in physics and accelerator technology.
TRIUMF (Canada’s particle accelerator centre) and SCK•CEN (Belgian Nuclear Research Centre) signed a Memorandum of Understanding (MOU) to formalize cooperation between these two leading international research facilities. The bilateral collaboration agreement was officially signed by Eric van Walle, SCK•CEN Director General, and TRIUMF Director Dr. Jonathan Bagger, in attendance of the King and the Queen of Belgium, the Foreign Affairs Minister Didier Reynders and the Secretary of State for Foreign Trade Pieter De Crem, also Special Envoy of the federal authorities for the MYRRHA research program.
TRIUMF and SCK•CEN will work jointly in the field of rare isotope production, with a particular focus on research and technology. Both centres, with their shared interests, open together a new realm of possibilities to leverage their assets and break through the frontiers of discovery and innovation in favour of their respective countries.
"Our research centres are powerful engines for discovery and innovation,” said TRIUMF Director Jonathan Bagger. “With our two organizations coming together, we have an incredible opportunity to leverage our infrastructure assets like ARIEL, ISAC, and MYRRHA, our multidisciplinary expertise and wide-spread networks to push new frontiers of possibility for the benefit of both science and society. ”
“We warmly welcome this new collaboration agreement between our two countries”, explains Eric van Walle, Director-General of SCK•CEN. “It is absolutely needed to share our expertise to advance nuclear science and technology, and to respond to large societal challenges. Thanks to the MYRRHA research infrastructure, we will be in a position to offer a technological solution not only for the treatment of spent nuclear fuel, but also to develop new types of medical radio-isotopes like the alpha-emitters that are crucial for the treatment of diseases like cancer.”